Floatz logo

Therapeutic Asset Ratings

470 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Zimberelimab
Classic Hodgkin Lymphoma
Sun Yat-sen UniversityP2CCC (53)
Zuberitamab
Follicular Lymphoma
Sun Yat-sen UniversityP2CCC (53)
egf816
Carcinoma, Non-Small-Cell Lung
Sun Yat-sen UniversityP3CCC (52)
Catequentinib
Her2-Receptor Negative Breast Cancer
Sun Yat-sen UniversityP2CCC (52)
Ensartinib
Lung Cancer
Sun Yat-sen UniversityP2CCC (52)
Neurotropin
Colorectal Cancer
Sun Yat-sen UniversityP3CCC (51)
Dfn-15
Liver Metastases
Sun Yat-sen UniversityP2CCC (51)
Dfn-15
Neoadjuvant Therapy
Sun Yat-sen UniversityP2CCC (51)
Donafenib
Intrahepatic Cholangiocarcinoma
Sun Yat-sen UniversityP2CCC (51)
Envafolimab
Immunotherapy
Sun Yat-sen UniversityP2CCC (51)
Envafolimab
Neoadjuvant Therapy
Sun Yat-sen UniversityP2CCC (51)
Epirubicin
Minimal Residual Disease
Sun Yat-sen UniversityP2CCC (51)
Iparomlimab
Clear Cell Renal Cell Carcinoma
Sun Yat-sen UniversityP2CCC (51)
Iparomlimab
Immunotherapy
Sun Yat-sen UniversityP2CCC (51)
Ivonescimab
Rectum Adenocarcinoma
Sun Yat-sen UniversityP2CCC (51)
Lubiprostone
Colorectal Cancer
Sun Yat-sen UniversityP2CCC (51)
PROPRANOLOL
Immunotherapy
Sun Yat-sen UniversityP2CCC (51)
Pucotenlimab
Intrahepatic Cholangiocarcinoma
Sun Yat-sen UniversityP2CCC (51)
Pucotenlimab
Neoadjuvant Therapy
Sun Yat-sen UniversityP2CCC (51)
Regorafenib
Liver Metastases
Sun Yat-sen UniversityP2CCC (51)
Tisleizumab
Immunotherapy
Sun Yat-sen UniversityP2CCC (51)
Trifluorouracil Tepidopyrimidine
Immunotherapy
Sun Yat-sen UniversityP2CCC (51)
Tuvonralimab
Immunotherapy
Sun Yat-sen UniversityP2CCC (51)
Vorolanib
Neoadjuvant Therapy
Sun Yat-sen UniversityP2CCC (51)
Zanubrutinib
Colorectal Cancer (CRC)
Sun Yat-sen UniversityP2CCC (51)
Showing 301 to 325 of 470 assets
PreviousPage 13 of 19Next